Biblio
Export 469 results:
[ Author
Filters: Keyword is Alzheimer Disease [Clear All Filters]
“Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.”, J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
, “Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings.”, J Alzheimers Dis, vol. 51, no. 2, pp. 545-61, 2016.
, “Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”, J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
, “Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
, “Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 345-57, 2016.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Lower Prevalence of Alzheimer's Disease among Tibetans: Association with Religious and Genetic Factors.”, J Alzheimers Dis, vol. 50, no. 3, pp. 659-67, 2016.
, “Investigating Causal Relations Between Circulating Metabolites and Alzheimer's Disease: A Mendelian Randomization Study.”, J Alzheimers Dis, vol. 87, no. 1, pp. 463-477, 2022.
, “Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.”, J Alzheimers Dis, vol. 61, no. 1, pp. 265-281, 2018.
, “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
, “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
, “Economic Burden of Alzheimer's Disease Dementia in Japan.”, J Alzheimers Dis, vol. 81, no. 1, pp. 309-319, 2021.
, “Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer's Disease Research.”, J Alzheimers Dis, vol. 80, no. 3, pp. 927-940, 2021.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “It's Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimer's Disease Research?”, J Alzheimers Dis, vol. 90, no. 4, pp. 1401-1415, 2022.
, “The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.”, J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
, “Cognitive Function Associated with Gut Microbial Abundance in Sucrose and S-Adenosyl-L-Methionine (SAMe) Metabolic Pathways.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1115-1130, 2022.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.”, J Alzheimers Dis, vol. 49, no. 3, pp. 593-605, 2016.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.”, Nature, vol. 488, no. 7409, pp. 96-9, 2012.
,